Back to search

From the notice

This technology from scientists at Los Alamos National Laboratory represents a novel platform for improving the safety and effectiveness of therapeutic gas-based treatments by enabling controlled, localized delivery at the site of disease. By addressing longstanding challenges associated with systemic exposure and dosing precision, the platform enhances the clinical viability of gas therapies across high-value markets such as oncology, cardiovascular care, and regenerative medicine. In addition, the inclusion of a complementary predictive modeling capability supports treatment optimization and development efficiency, reducing technical risk and accelerating translation. Together, these capabilities position the technology as a differentiated and scalable solution that can unlock new commercial opportunities in areas where gas-based therapeutics have shown promise but faced delivery limitations. The Opportunity: Therapeutic gases have demonstrated meaningful biological effects across oncology, cardiovascular disease, neuroprotection and regenerative medicine, yet their clinical adoption has been limited by a fundamental challenge: safe, controlled and localized delivery. Existing approaches often result in rapid release, systemic exposure or narrow therapeutic windows, creating safety, regulatory and development barriers. The Clathrate Therapeutics Platform addresses this unmet need by positioning gas-based therapies as programmable, targetable and commercially viable treatmen

We may have shortened this. The official posting is the record. We are not affiliated with the agency that published it.